Charles Zhu
Stock Analyst at LifeSci Capital
(2.52)
# 2,158
Out of 4,791 analysts
24
Total ratings
47.62%
Success rate
13.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.07 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $1.37 | +483.94% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.22 | +883.61% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $43.01 | +11.60% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $70.46 | -20.52% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $4.29 | +412.82% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $5.72 | +354.55% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $16.35 | +95.72% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $11.92 | +17.45% | 2 | May 5, 2022 |
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.07
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $1.37
Upside: +483.94%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.22
Upside: +883.61%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $43.01
Upside: +11.60%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $70.46
Upside: -20.52%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $4.29
Upside: +412.82%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $5.72
Upside: +354.55%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $16.35
Upside: +95.72%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $11.92
Upside: +17.45%